Mereo BioPharma Group plc financial data

Symbol
MREO on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Cavendish Place, Fourth Floor, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 594 %
Debt-to-equity 25.7 %
Return On Equity -74.1 %
Return On Assets -59 %
Operating Margin -3.92K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 776M shares
Entity Public Float 144M USD
Common Stock, Value, Issued 3.05M USD
Weighted Average Number of Shares Outstanding, Basic 770M shares +12.4%
Weighted Average Number of Shares Outstanding, Diluted 770M shares +12.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1M USD
Research and Development Expense 16.9M USD -11.8%
General and Administrative Expense 23.6M USD +8.67%
Operating Income (Loss) -39.2M USD -3.38%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -45.8M USD -130%
Income Tax Expense (Benefit) -532K USD
Net Income (Loss) Attributable to Parent -45.3M USD -130%
Earnings Per Share, Basic -0.06 USD/shares -100%
Earnings Per Share, Diluted -0.06 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 80.5M USD
Assets, Current 86.7M USD
Property, Plant and Equipment, Net 315K USD
Operating Lease, Right-of-Use Asset 909K USD
Intangible Assets, Net (Excluding Goodwill) 1.09M USD
Assets 88.7M USD
Accounts Payable, Current 1.75M USD
Accrued Liabilities, Current 3.53M USD
Liabilities, Current 14.2M USD
Operating Lease, Liability, Noncurrent 394K USD
Other Liabilities, Noncurrent 568K USD
Liabilities 16.2M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -11.1M USD
Retained Earnings (Accumulated Deficit) -456M USD
Stockholders' Equity Attributable to Parent 72.5M USD +32.6%
Liabilities and Equity 88.7M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.99M USD +13.6%
Net Cash Provided by (Used in) Investing Activities -700K USD -67.1%
Common Stock, Shares, Issued 774M shares
Common Stock, Par or Stated Value Per Share 0 GBP/shares
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD -99.4%
Deferred Tax Assets, Valuation Allowance 206M USD +4.61%
Deferred Tax Assets, Gross 206M USD +4.61%
Operating Lease, Liability 1.13M USD
Depreciation 170K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.8M USD +22.6%
Lessee, Operating Lease, Liability, to be Paid 1.23M USD
Property, Plant and Equipment, Gross 1.28M USD
Operating Lease, Liability, Current 736K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 111M USD +5.46%
Operating Lease, Payments 807K USD +2.59%
Additional Paid in Capital 536M USD
Amortization of Intangible Assets 108K USD +68.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Operating Leases, Future Minimum Payments Due 1.54M USD
Interest Expense 1.35M USD -49.6%